Description
Latin name
Clenil
Release form
Suspension for inhalation.
Packaging
In a strip of 5 plastic ampoules of 2 ml. In a cardboard box 4 strips.
Pharmacological action
Klenil UDV has anti-inflammatory and anti-allergic effects. It inhibits the release of inflammatory mediators, increases the production of lipomodulin, a phospholipase A inhibitor, reduces the release of arachidonic acid, and inhibits the synthesis of prostaglandins. Prevents marginal accumulation of neutrophils, reducing the formation of inflammatory exudate and the production of lymphokines, inhibits the migration of macrophages, which leads to a slowdown in the processes of infiltration and granulation.
Increases the number of active a-adrenoreceptors, neutralizes their desensitization, restores the patient’s reaction to bronchodilators, allowing to reduce the frequency of their use.
Under the action of beclomethasone, the number of mast cells in the bronchial mucosa decreases, reduced edema of the epithelium and secretion of mucus by the bronchial glands. It causes relaxation of the smooth muscles of the bronchi, reduces their hyperreactivity and improves external respiration function. It does not have mineralocorticoid activity. In therapeutic doses, it does not cause side effects characteristic of systemic corticosteroids. With intranasal use, it eliminates edema, hyperemia of the nasal mucosa. The therapeutic effect usually develops after 5-7 days of course use of beclomethasone. With external and local application it has anti-allergic and anti-inflammatory effects.
Indications
For inhalation use: treatment of bronchial asthma (including with insufficient effectiveness of bronchodilators and / or cromolyn sodium, as well as severe hormone-dependent bronchial asthma in adults and children).
For intranasal use: prevention and treatment of perennial and seasonal allergic rhinitis, including rhinitis with hay fever, vasomotor rhinitis.
For external and local use: in combination with antimicrobial agents – infectious and inflammatory diseases of the skin and ear.
Contraindications
– Severe asthma attacks requiring intensive care.
– Tuberculosis.
– Candidomycosis of the upper respiratory tract.
– I trimester of pregnancy.
– Hypersensitivity to beclomethasone.
Use during pregnancy and lactation
Use in the second and third trimesters of pregnancy is possible only if the intended benefit to the mother outweighs the potential risk to the fetus. Newborns whose mothers received beclomethasone during pregnancy should be carefully monitored for adrenal insufficiency.
If necessary, use during lactation should decide on the termination of breastfeeding.
Composition
1 ampoule contains: beclomethasone dipropionate 800 mcg.
Excipients: polysorbate 20, sorbitan laurate, sodium chloride, purified water.
Dosage and administration of
For adults, by inhalation, the average dose is 400 mcg / day, the frequency of use is 2-4 times / day. If necessary, the dose can be increased to 1 g / day.
For children, a single dose is 50-100 mcg, the frequency of use is 2-4 times / day.
With intranasal administration, the dose is 400 mcg / day, the frequency of use is 1-4 times / day.
For topical and topical use, the dose depends on the indications and the dosage form used.
Drug interaction
With the simultaneous use of beclomethasone with other corticosteroids for systemic or intranasal use, it is possible to increase the suppression of adrenal cortex function.
Previous inhaled beta-adrenergic stimulants may increase the clinical efficacy of beclomethasone.
Storage Conditions
Store at a temperature not exceeding 25 C, in the original packaging for protection against light, away from heating appliances, in an upright position.
Expiration
2 years.
active substance
Beclomethasone
Dosage form
suspension for inhalation
